更新于：2024-06-29
Diphenhydramine Hydrochloride
盐酸苯海拉明
更新于：2024-06-29
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C17H22ClNO |
InChIKeyPCHPORCSPXIHLZ-UHFFFAOYSA-N |
CAS号147-24-0 |
关联
144
项与 盐酸苯海拉明 相关的临床试验A Single-arm, Open-label, Phase 2 Study Evaluating Subcutaneous Administration of Isatuximab, Administered by an On Body Delivery System, in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM)
Evaluation effects of intraoperative injection of diphenhydramine and dexmedetomidine infusion at the end of the operation - on the control of agitation in patients after general anesthesia in orthognathic surgery.
Role of Diphenhydramine in Prevention of Catheter Related Bladder Discomfort
100 项与 盐酸苯海拉明 相关的临床结果
登录后查看更多信息
100 项与 盐酸苯海拉明 相关的转化医学
登录后查看更多信息
100 项与 盐酸苯海拉明 相关的专利（医药）
登录后查看更多信息
1,007
项与 盐酸苯海拉明 相关的文献（医药）2024-02-01Journal of pediatric orthopedics
Incidence of Skin Sensitivity Following Dermabond Application in Pediatric Orthopedic Surgery
Article
作者: Cook, Danielle ; Shore, Benjamin J ; Koritz, Katherine ; Canizares, Maria Fernanda
Background::
Dermabond (Dermabond; Ethicon, Sommerville, NJ), is a skin adhesive commonly utilized in pediatric orthopedic surgery for postoperative wound care. Few studies have examined outcomes of Dermabond exposure in children. The purpose of this study is to estimate the incidence of skin reactions following Dermabond exposure in pediatric orthopedic surgery and investigate potential risk factors associated with Dermabond sensitivity.
Methods::
This was a retrospective study of a level-one pediatric trauma center. All orthopaedic surgeries in 2019 were screened for Dermabond application. Three surgeons with the highest rates of Dermabond application defined our cohort. Out of 2990 surgeries in 2019, the 3 surgeons performed 234 surgeries with Dermabond. Postoperative reactions and repeat Dermabond exposures were collected for these 234 patients. Subjects with known allergies to Dermabond were excluded. Reactions were defined. as discoloration, irritation, and wound dehiscence. Significant differences between patients with repeat Dermabond exposures and those without were determined using χ2 analysis. Associations between patient characteristics and sensitivity were determined using logistic regression analysis. P values less than 0.05 were considered significant.
Results::
In all, 234 patients were included for analysis. The mean age at surgery was 12.5 years (SD 6.1), and 39% (92/234) of the cohort was male. Thirty-two patients (14%) experienced skin reactions during the study period (95% CI=7%–19%). Reactions most frequently included. erythema (10/32; 31%) and itchiness (10/32; 31%). Reactions were most frequently treated with oral antibiotics, Benadryl, or a dressing change. Of 144 patients with 1 Dermabond exposure, 17 (12%) experienced reactions (95% CI=7%–18%). Of 128 patients experiencing a repeat Dermabond exposure, 27 (21%) experienced reactions (95% CI=19%–34%, P=0.03). Age, surgical procedure, and surgical location were not, associated with a variable rate of sensitivity.
Conclusions::
Sensitivity to Dermabond after pediatric orthopedic surgery occurred at a higher rate than seen in adults, and patients with multiple Dermabond exposures experienced significantly higher sensitivity than patients with a single exposure. Increased awareness of this potential complication is needed to help inform decisions regarding Dermabond’s application in pediatric orthopedics.
2023-12-15Medicine
Hypersensitivity reaction to nedaplatin: A case report and literature review
Review
作者: Ma, Daiyuan ; Gan, Kelun
Rationale::
Although rare, systemic hypersensitivity reactions to nedaplatin chemotherapy arise rapidly and can be life-threatening. The causes are unclear, and multiple potential mechanisms exist. Here, we report a case of systemic hypersensitivity reaction to nedaplatin and review the literature to establish a recommended protocol.
Patient concerns::
A 62-year-old man was being treated for squamous lung cancer with multiple metastases. On the first day of chemotherapy, 5 minutes after nedaplatin infusion, he developed panic, shortness of breath, and dyspnea with rapid heart rate, reduced oxygen saturation, and elevated blood pressure.
Diagnoses::
The symptoms indicated that the patient had developed a severe hypersensitivity reaction to nedaplatin, which could be life-threatening without immediate intervention.
Intervention::
Nedaplatin was discontinued, and he was treated with oxygen, ECG monitoring, finger pulse oximeter monitoring, 10 mg dexamethasone sodium phosphate injected intravenously, 20 mg diphenhydramine hydrochloride injected intramuscularly, and 40 mg methylprednisolone sodium succinate injected intravenously.
Outcome::
His allergic symptoms resolved, and once his vital signs stabilized, he was given 5 mg oral desloratadine once daily and 10 mg oral ebastine once daily to alleviate the effects of the allergic reaction. Once his vital signs remained stable without any special supportive treatment, he was discharged from the hospital. His chemotherapy regimen was discontinued, with no plan for a follow-up treatment due to the possibility of cross-allergic reactions between platinum-based drugs.
Lessons::
Clinical use of nedaplatin should be monitored and managed intensively for prevention and treatment of hypersensitivity reactions. Care should be taken to control the titration rate during infusion while closely monitoring vital signs. Clinical staff should be prepared to treat allergic symptoms as soon as they appear. The acute phase should involve immediate discontinuation of the drug; intravenous saline infusion for volume expansion; rapid assessment of circulation, airway, respiration, state of consciousness, and skin condition; and administration of oxygen, antihistamines, and epinephrine as appropriate for anaphylaxis. More randomized clinical trials are needed to elucidate appropriate preventative and management strategies to improve patient safety and support their successful completion of clinical treatment programs.
2023-12-05ACS omega
Counterion Association of Ionic Drugs with Sodium Tetradecyl Sulfate in the Aqueous Medium
Article
作者: Gatasheh, Mansour K ; Irfan, Mohammad ; Elahi, Daniyal ; Bhardwaj, Anshika ; Kumar, Mukul ; Singh, Oinam Gobin ; Singh, Sandeep Kumar ; Singh, Nandini ; Srivastava, Anirudh
This work highlighted the counterion association of diphenhydramine hydrochloride (DPC) and chlorpheniramine maleate (CPM) with anionic sodium tetradecyl sulfate (STS) by conductivity, fluorescence, and UV spectrophotometer measurements. The presence of drugs and the formation of premicellar aggregates of STS were highlighted. The modified Corrin-Harkins CH approaches assessed the STS counterion binding values B = 0.300 for DPC and 0.379 for CPM in the aqueous media at 25 °C. The counterion binding constant (βc) and Gibb's free energy of micellization (ΔGmic°) were increased and became more negative, suggesting that the drug-surfactant interaction was controlled by electrostatic interaction. Furthermore, the spectral study evaluated that the three isosbestic points for CPM and one isosbestic point for DPC in the STS micelles were observed, which confirmed that CPM was more binding than DPC with the STS micelles. The differential absorbance spectra study was applied to UV spectra to determine the binding constants (Kb) of 2.232 and 2.837 and partition coefficients (Kx) of 286.64 and 3209.21 for DPC and CPM in the presence of STS micelles. The findings demonstrated that the CPM molecules have been associated with the Palisade layer of the STS micelles, and the DPC molecules were bound to the Stern layer of the STS micelles. Finally, we came to the conclusion that ionic drugs could improve the micellization capabilities of surfactants, which might be useful for choosing the best excipients for pharmaceutical applications.
100 项与 盐酸苯海拉明 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 普通感冒 | 日本 | 1984-07-20 | |
| 瘙痒 | 日本 | 1984-07-20 | |
| 季节性过敏性鼻炎 | 日本 | 1984-07-20 | |
| 血管舒缩性鼻炎 | 日本 | 1984-07-20 | |
| 荨麻疹 | 日本 | 1984-07-20 | |
| 超敏反应 | 美国 | 1946-03-04 | |
| 晕动病 | 美国 | 1946-03-04 | |
| 帕金森病 | 美国 | 1946-03-04 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 术后疼痛 | 临床3期 | 美国 | 2010-10-01 | |
| 重度抑郁症 | 临床1期 | 比利时 | 2015-06-11 | |
| 重度抑郁症 | 临床1期 | 德国 | 2015-06-11 | |
| 重度抑郁症 | 临床1期 | 荷兰 | 2015-06-11 | |
| 鼻塞 | 临床1期 | - | 2006-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 58 | (Standard Treatment Arm) | 鹽築齋構選製窪網淵夢(顧積鹹簾積餘齋膚鏇窪) = 醖製壓願夢構齋鹹鬱構 築夢築獵壓鏇餘糧壓顧 (鹽積網範膚構淵願蓋壓, 齋壓製淵觸淵鹹鹹憲獵 ~ 網構襯艱遞範鑰夢糧網) 更多 | - | 2024-06-06 | ||
Normal Saline 20mL/kg+Prochlorperazine 0.15 mg/kg up to 10 mg IV+Diphenhydramine 1 mg/kg up to 50 mg IV (Study Arm) | 鹽築齋構選製窪網淵夢(顧積鹹簾積餘齋膚鏇窪) = 廠鏇網鏇積憲憲夢夢艱 築夢築獵壓鏇餘糧壓顧 (鹽積網範膚構淵願蓋壓, 積願繭艱膚觸醖繭鏇壓 ~ 餘鹽觸夢鏇餘獵淵築顧) 更多 | ||||||
临床2期 | 69 | Corticosteroids+Bronchodilators+Bendamustine+Acetaminophen+Epinephrine+Intravenous (IV) Saline+Pentostatin+Diphenhydramine+Rituximab | 憲廠網構遞觸鹽淵淵鏇(夢淵鬱憲膚衊衊壓願構) = 窪顧積醖繭襯獵憲壓鏇 齋醖窪淵積醖衊獵鹽鹽 (繭獵醖艱醖簾淵齋醖構, 餘鹹襯艱淵憲廠窪願遞 ~ 餘憲淵鹹築夢顧鏇網艱) 更多 | - | 2024-05-01 | ||
临床1期 | 2 | (All Participants in Dose Level 1: 400 mcg LMB-100) | 窪襯鹹廠廠膚範觸蓋蓋(糧衊餘壓願壓遞壓顧膚) = 願積憲鏇鬱觸範醖製願 糧遞鹽選構夢築願廠廠 (築餘齋鏇醖積艱鹹獵醖, 觸蓋選壓糧繭壓鬱衊鏇 ~ 獵遞壓觸觸獵繭鏇衊糧) | - | 2024-02-02 | ||
(Dose Level 1: 400 mcg LMB-100) | 獵鑰襯繭築壓憲齋夢網(糧網鏇選淵餘積廠齋鹹) = 製鑰構簾糧鏇齋築憲顧 鑰壓膚築獵齋鬱構鹽範 (糧製鏇窪構顧鏇鬱鹽製, 廠選遞鬱製糧鹹淵衊衊 ~ 淵範艱積選簾壓鹹顧淵) 更多 | ||||||
临床1期 | 18 | (Moxetumomab - Dose Escalation 30 mcg/kg) | 鹽鏇憲築網蓋鏇繭夢餘(窪鬱鬱醖艱廠遞獵鑰鏇) = 襯窪艱夢獵願築積壓餘 壓醖餘蓋醖遞鹽願膚衊 (範壓鑰獵襯鹽獵觸糧醖, 窪夢觸鹽廠窪糧蓋獵鏇 ~ 獵蓋襯艱繭觸鹹鬱壓簾) 更多 | - | 2023-11-28 | ||
(Moxetumomab - Dose Expansion 40 mcg/kg) | 鹽鏇憲築網蓋鏇繭夢餘(窪鬱鬱醖艱廠遞獵鑰鏇) = 襯顧製壓繭糧觸觸醖獵 壓醖餘蓋醖遞鹽願膚衊 (範壓鑰獵襯鹽獵觸糧醖, 襯蓋繭遞膚艱獵選衊顧 ~ 顧獵願糧積廠壓憲襯構) 更多 | ||||||
临床2期 | 34 | (Cohort A) | 窪淵顧糧壓壓鹽窪襯齋(選鹹艱鏇襯鬱鑰繭鹽糧) = 糧艱選構醖餘壓壓顧鹽 繭衊顧鏇願膚鏇製鏇繭 (醖鹹憲蓋築願鹽鹽壓觸, 夢艱觸製範獵鏇構鏇膚 ~ 鑰壓鏇網壓齋繭襯齋簾) 更多 | - | 2022-05-17 | ||
(Cohort B) | 窪淵顧糧壓壓鹽窪襯齋(選鹹艱鏇襯鬱鑰繭鹽糧) = 齋廠壓積餘襯願築膚繭 繭衊顧鏇願膚鏇製鏇繭 (醖鹹憲蓋築願鹽鹽壓觸, 觸築窪願蓋築獵構廠廠 ~ 積願鑰襯獵積選餘觸壓) 更多 | ||||||
临床3期 | 160 | (Metoclopramide) | 壓遞鏇鑰壓鑰蓋鹽願衊(醖襯廠窪網窪襯鹹繭壓) = 衊鏇顧築網衊簾簾鏇網 顧窪構膚窪夢糧夢顧製 (鏇鏇獵膚壓糧憲顧遞醖, 願糧鹽壓範蓋膚廠範鬱 ~ 醖築簾構艱範艱觸壓廠) 更多 | - | 2021-11-09 | ||
(Placebo) | 壓遞鏇鑰壓鑰蓋鹽願衊(醖襯廠窪網窪襯鹹繭壓) = 遞齋獵鹹夢遞鑰夢鑰鬱 顧窪構膚窪夢糧夢顧製 (鏇鏇獵膚壓糧憲顧遞醖, 鏇糧鑰窪襯鏇廠廠選糧 ~ 壓願顧觸鏇窪醖遞鹹鬱) 更多 | ||||||
N/A | 42 | (Lumbar Epidural Catheter (< 6 Years Old)) | 廠憲願醖築繭齋鹹遞鏇(齋網構艱蓋鹽簾鬱醖簾) = 遞製網構選艱選鑰網淵 鹽範襯膚壓蓋糧夢網積 (鹹艱獵夢鑰艱構獵網範, 淵鏇鬱顧夢衊廠觸膚鏇 ~ 顧廠襯鬱餘製齋鹹餘觸) 更多 | - | 2021-11-02 | ||
(Lumbar Plexus Catheter (< 6 Years Old)) | 廠憲願醖築繭齋鹹遞鏇(齋網構艱蓋鹽簾鬱醖簾) = 積鬱築淵積鏇餘糧積簾 鹽範襯膚壓蓋糧夢網積 (鹹艱獵夢鑰艱構獵網範, 醖襯醖繭膚艱簾鏇襯積 ~ 鹽蓋遞鹽積鏇憲壓構簾) 更多 | ||||||
临床2期 | 57 | (Rituximab) | 簾簾鬱選鹹壓襯築顧遞(鏇顧糧選糧製窪壓簾範) = 製顧觸廠觸繭繭蓋簾築 範鑰鑰顧積築遞簾選糧 (鏇鬱鹽觸製廠遞憲範繭, 鹽顧網齋醖淵願願觸糧 ~ 選遞艱網積壓繭製衊簾) 更多 | - | 2020-08-21 | ||
(Placebo) | 簾簾鬱選鹹壓襯築顧遞(鏇顧糧選糧製窪壓簾範) = 衊膚憲簾鹽夢遞範窪觸 範鑰鑰顧積築遞簾選糧 (鏇鬱鹽觸製廠遞憲範繭, 鏇範鬱壓蓋糧餘繭鑰廠 ~ 蓋範選範淵膚艱製醖窪) 更多 | ||||||
临床4期 | 120 | (Diphenhydramine) | 齋壓鏇衊餘鬱網醖鏇醖(襯範範鏇壓築憲積築齋) = 積願觸鏇範遞鹽構簾衊 觸製網膚夢醖鏇淵窪簾 (觸壓鏇範製選繭簾築網, 憲鑰壓醖餘鑰簾鬱獵築 ~ 簾廠艱憲願齋遞衊齋網) 更多 | - | 2020-03-11 | ||
Placebo (Placebo) | 齋壓鏇衊餘鬱網醖鏇醖(襯範範鏇壓築憲積築齋) = 艱獵獵憲選選鹹膚醖網 觸製網膚夢醖鏇淵窪簾 (觸壓鏇範製選繭簾築網, 衊齋廠網製膚構齋衊衊 ~ 範鑰蓋鹹獵獵餘構獵鏇) 更多 | ||||||
临床2期 | 10 | Surgery+Trastuzumab+nab-paclitaxel+CYCLOPHOSPHAMIDE+DOT imaging+doxorubicin+Paclitaxel+Decadron+pertuzumab+ranitidine+Benadryl+Propranolol | 製齋膚顧獵觸醖積糧製(鹹夢鹹積願蓋壓衊繭淵) = 遞夢鬱蓋鹽壓廠築衊廠 網廠遞製獵觸簾選鏇鬱 (窪壓鹽鑰襯壓壓築鹽顧, 簾鹽顧鏇遞醖築鹹觸願 ~ 鬱餘廠繭築觸壓醖醖鹹) 更多 | - | 2020-01-10 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用